Bristol-Myers Squibb completes $4.5B note offering to finance Mirati acquisition

BRISTOL MYERS SQUIBB CO

$4.5B note offering completed: $1B 5.75% due 2031, $1B 5.9% due 2033, $1.25B 6.25% due 2053, $1.25B 6.4% due 2063.
Proceeds to fund general corporate purposes, including the proposed acquisition of Mirati Therapeutics.
Offering closed November 13, 2023; underwritten by syndicate of banks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.